Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study on Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy (FOLFOXIRI/ Bevacizumab)

NCT01126866 is registered in ClinicalTrials.gov with National Center for Tumor Diseases, Heidelberg as lead sponsor.

NCT NCT01126866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01126866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study on Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy (FOLFOXIRI/ Bevacizumab)
Lead sponsor
National Center for Tumor Diseases, Heidelberg
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2009
Completion date
June 30, 2011
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma